Supernus Pharmaceuticals (SUPN) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Supernus Pharmaceuticals is expected to report Q3 2026 results after market close on October 29, with analysts forecasting $0.49 in earnings per share and $217.56 million in revenue.
• In its prior quarter, the company posted a significant EPS loss of $1.01, missing estimates, although revenue rose 32.4% year over year to $219.06 million and exceeded expectations.
• Investor sentiment is mixed: the stock carries a consensus “Hold” rating and a $62.40 price target, while shares recently traded near $41.21 amid several analyst downgrades.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) is expected to be posting its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect Supernus Pharmaceuticals to announce earnings of $0.49 per share and revenue of $217.56 million for the quarter. Investors are encouraged to explore the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of $0.42 by ($1.43). The company had revenue of $219.06 million for the quarter, compared to analyst estimates of $205.31 million. Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%. Supernus Pharmaceuticals's revenue was up 32.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.40 earnings per share. On average, analysts expect Supernus Pharmaceuticals to post $2.05 EPS for the current fiscal year and $3.95 EPS for the next fiscal year.

Supernus Pharmaceuticals Price Performance

Shares of SUPN stock opened at $41.21 on Thursday. The firm has a fifty day moving average of $43.36 and a two-hundred day moving average of $46.16. The firm has a market cap of $2.40 billion, a P/E ratio of -21.46, a P/E/G ratio of 1.06 and a beta of 0.55. Supernus Pharmaceuticals has a 1-year low of $37.54 and a 1-year high of $59.68.

Wall Street Analysts Forecast Growth

SUPN has been the topic of several research analyst reports. Zacks Research cut shares of Supernus Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Monday, October 5th. Weiss Ratings reiterated a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a research note on Monday, September 21st. Wall Street Zen downgraded Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Finally, Cantor Fitzgerald boosted their price objective on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an "overweight" rating in a report on Thursday, July 9th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat, Supernus Pharmaceuticals has a consensus rating of "Hold" and a consensus price target of $62.40.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company's activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus' marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.